NCT06851403View on ClinicalTrials.gov

The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study

Enrolling by invitationOBSERVATIONAL
Enrollment

213

Participants

Timeline

Start Date

January 30, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Asthma in Children
Interventions
DRUG

Dupilumab

initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks

Trial Locations (1)

510120

Guangzhou institute of respiratory disease, Guangzhou

All Listed Sponsors
lead

Guangzhou Institute of Respiratory Disease

OTHER